leisure time -WSS

leisure time

author：explore 2025-10-01 21:37:11 - browse：1865

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Venture capitalist Bob Kocher on the state of digital health

explore

WSS

Arc Institute generative AI designs new CRISPR systems

HIV vaccine remains elusive. Immunologists keep trying new ideas

Change Healthcare cyberattack prompts Medicare loan program

NEJM study link tiny plastics in blood vessels to heart problems

NEJM study link tiny plastics in blood vessels to heart problems

Addiction experts warn against a second 'war on drugs'

hotspot

leisure time

leisure time

Apple is now the first public company to be valued at $3 trillion

NVIDIA and Google execs on the future of AI and drug discovery

ChatGPT in medicine: STAT answers readers' burning questions

Cytokinetics CEO stresses company can launch heart drug on its own

Novavax promises a turnaround & Lilly roils the obesity market

How to bring more disabled researchers into academia

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

New air purifier tech could be key to improving indoor air quality

Readout LOUD podcast: Live from STAT Breakthrough Summit West

hotspot

IVF, abortion rights issues kick off Biden’s State of the Union

Headspace, Meta partner to launch VR meditation app for Quest

It's time to retire 'poor historian' from clinicians' vocabularies

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Second House panel advances two

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

hotspot

hotspot

explore

hotspot